Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
Eur Cell Mater ; 41: 170-183, 2021 02 13.
Article in English | MEDLINE | ID: mdl-33580967

ABSTRACT

The aim of the present study was to investigate in vivo whether bone morphogenetic protein-7 (BMP-7) was able to promote and accelerate dental implant healing at a low dose in an osteopenic environment by using a delayed drug-release system. Skeletally mature Chinese goats, having physiologically osteopenic (osteoporotic-like) facial bones, served as an animal model. Dental implants were provided with a delayed-release drug-delivery system and BMP-7 was applied at three different dosages. The implants, inserted into healed extraction sockets, were removed 1, 2 and 3 weeks after surgery. Quantification of osseointegration and formation of new bone in the peri- implant space were measured histomorphometrically. Data revealed no evidence of any adverse drug effect at or near the implantation sites. After the first postoperative week, bone neoformation was minimal; after the second week, peri-implant bone formation appeared, particularly in the groups with low dosages of BMP-7. After 3 weeks, new-bone volume was the largest in the group with the lowest (near-physiological) dosage of BMP-7, also showing the highest efficacy of BMP-7. Other dosage or release modes were found to be significantly less effective. BMP-7 was highly efficacious in promoting and accelerating bone formation in the peri-implant space in a hostile osteopenic environment if released by a slow-mode mechanism over time at near physiological activities. Therefore, biological functionalisation of dental implants by a high-power osteogenic factor may improve their healing success in hostile bony environments (osteopenia, osteoporosis, bone atrophy etc.).


Subject(s)
Bone Morphogenetic Protein 7 , Dental Implants , Animals , Bone Morphogenetic Protein 2 , Osseointegration , Osteogenesis
2.
Eur Cell Mater ; 32: 241-256, 2016 11 18.
Article in English | MEDLINE | ID: mdl-27858400

ABSTRACT

In clinical orthopaedics, total joint replacements and spinal fusions are routine undertakings. Many of the implicated patients suffer from osteoporosis, severe arthrosis or osteopaenia. In individuals thus afflicted, the bony bed lacks the mechanical stability that is a requisite for a firm anchorage of the implant and its functional competence. To promote the bony bondage of an implant it is necessary to induce neo-ossification by the introduction of an osteogenic agent, such as bone morphogenetic protein 2 (BMP-2). Since this growth factor is generally applied in a free form and at high dosages to maximise its osteogenicity, untoward side effects frequently ensue. We hypothesise that the administration of BMP-2 using a suitable delivery vehicle, and its gradual, low dose release therefrom in a cell-mediated manner, would avert the triggering of undesired side effects and enhance its efficacy. To test this postulate, implants of porous titanium were coated with a layer of calcium phosphate into which BMP-2 was biomimetically incorporated at dosages ranging from 0.8 to 500 µg/g of coating material (delivery system) prior to their surgical placement in the tibiae of adult sheep. The volume and the surface area of newly-formed bone were evaluated histomorphometrically after 3 and 6 weeks. The highest values were achieved using BMP-2 dosages of 20 to 100 µg/g of coating: The deposition of bone was confined to the immediate vicinity of the implant and was observed deep within the interstices of its meshwork, to the walls of which it bonded well. The findings of the study attest to the validity of our hypothesis.


Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Implants, Experimental , Osseointegration/drug effects , Titanium/pharmacology , Animals , Cancellous Bone/drug effects , Coated Materials, Biocompatible/pharmacology , Imaging, Three-Dimensional , Kinetics , Models, Animal , Organ Size/drug effects , Porosity , Sheep , Time Factors
4.
Neuroscience ; 297: 95-104, 2015 Jun 25.
Article in English | MEDLINE | ID: mdl-25841321

ABSTRACT

Attention-deficit/hyperactivity disorder (ADHD) is a complex neurobehavioral disorder that is characterized by attention difficulties, impulsivity, and hyperactivity. A non-stimulant drug, atomoxetine (ATX), which is a selective noradrenaline reuptake inhibitor, is widely used for ADHD because it exhibits fewer adverse effects compared to conventional psychostimulants. However, little is known about the therapeutic mechanisms of ATX. ATX treatment significantly alleviated hyperactivity of pituitary adenylate cyclase-activating polypeptide (PACAP)-deficient (PACAP(-/-)) mice with C57BL/6J and 129S6/SvEvTac hybrid background. ATX also improved impaired novel object recognition memory and prepulse inhibition in PACAP(-/-) mice with CD1 background. The ATX-induced increases in extracellular noradrenaline and dopamine levels were significantly higher in the prefrontal cortex of PACAP(-/-) mice compared to wild-type mice with C57BL/6J and 129S6/SvEvTac hybrid background. These results suggest that ATX treatment-induced increases in central monoamine metabolism may be involved in the rescue of ADHD-related abnormalities in PACAP(-/-) mice. Our current study suggests that PACAP(-/-) mice are an ideal rodent model with predictive validity for the study of ADHD etiology and drug development. Additionally, the potential effects of differences in genetic background of PACAP(-/-) mice on behaviors are discussed.


Subject(s)
Adrenergic Uptake Inhibitors/therapeutic use , Atomoxetine Hydrochloride/therapeutic use , Cognition Disorders/drug therapy , Hyperkinesis/drug therapy , Memory Disorders/drug therapy , Pituitary Adenylate Cyclase-Activating Polypeptide/deficiency , Prepulse Inhibition/drug effects , Acoustic Stimulation , Analysis of Variance , Animals , Biogenic Monoamines/metabolism , Cognition Disorders/genetics , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Hyperkinesis/etiology , Memory Disorders/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Microdialysis , Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Recognition, Psychology/drug effects
5.
Osteoarthritis Cartilage ; 23(3): 334-50, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25534362

ABSTRACT

OBJECTIVE: The repair of cartilaginous lesions within synovial joints is still an unresolved and weighty clinical problem. Although research activity in this area has been indefatigably sustained, no significant progress has been made during the past decade. The aim of this educational review is to heighten the awareness amongst students and scientists of the basic issues that must be tackled and resolved before we can hope to escape from the whirlpool of stagnation into which we have fallen: cartilage repair redivivus! DESIGN: Articular-cartilage lesions may be induced traumatically (e.g., by sports injuries and occupational accidents) or pathologically during the course of a degenerative disease (e.g., osteoarthritis). This review addresses the biological basis of cartilage repair and surveys current trends in treatment strategies, focussing on those that are most widely adopted by orthopaedic surgeons [viz., abrasive chondroplasty, microfracturing/microdrilling, osteochondral grafting and autologous-chondrocyte implantation (ACI)]. Also described are current research activities in the field of cartilage-tissue engineering, which, as a therapeutic principle, holds more promise for success than any other experimental approach. RESULTS AND CONCLUSIONS: Tissue engineering aims to reconstitute a tissue both structurally and functionally. This process can be conducted entirely in vitro, initially in vitro and then in vivo (in situ), or entirely in vivo. Three key constituents usually form the building blocks of such an approach: a matrix scaffold, cells, and signalling molecules. Of the proposed approaches, none have yet advanced beyond the phase of experimental development to the level of clinical induction. The hurdles that need to be surmounted for ultimate success are discussed.


Subject(s)
Arthroplasty, Subchondral , Bone Transplantation , Cartilage, Articular/surgery , Cartilage/transplantation , Chondrocytes/transplantation , Osteoarthritis/surgery , Cartilage, Articular/injuries , Humans , Orthopedic Procedures , Osteoarthritis/therapy , Tissue Engineering
6.
Neuroscience ; 238: 297-304, 2013 May 15.
Article in English | MEDLINE | ID: mdl-23454538

ABSTRACT

We previously demonstrated that the peptidergic neurotransmitter pituitary adenylate cyclase-activating polypeptide (PACAP) affects the autonomic system and contributes to the control of metabolic and cardiovascular functions. Previous studies have demonstrated the importance of centrally-mediated sympathetic effects of leptin for obesity-related hypertension. Here we tested whether PACAP signaling in the brain is implicated in leptin-induced sympathetic excitation and appetite suppression. In anesthetized mice, intracerebroventricular (ICV) pre-treatment with PACAP6-38, an antagonist of the PACAP receptors (PAC1-R and VPAC2), inhibited the increase in white adipose tissue sympathetic nerve activity (WAT-SNA) produced by ICV leptin (2µg). In contrast, leptin-induced stimulation of renal sympathetic nerve activity (RSNA) was not affected by ICV pre-treatment with PACAP6-38. Moreover, in PACAP-deficient (Adcyap1-/-) mice, ICV leptin-induced WAT-SNA increase was impaired, whereas RSNA response was preserved. The reductions in food intake and body weight evoked by ICV leptin were attenuated in Adcyap1-/- mice. Our data suggest that hypothalamic PACAP signaling plays a key role in the control by leptin of feeding behavior and lipocatabolic sympathetic outflow, but spares the renal sympathetic traffic.


Subject(s)
Adipose Tissue, White/drug effects , Kidney/drug effects , Leptin/pharmacology , Peptide Fragments/pharmacology , Pituitary Adenylate Cyclase-Activating Polypeptide/pharmacology , Sympathetic Nervous System/drug effects , Adipose Tissue, White/innervation , Adipose Tissue, White/metabolism , Animals , Body Weight/drug effects , Eating/drug effects , Hypothalamus/drug effects , Hypothalamus/metabolism , Injections, Intraventricular , Kidney/innervation , Kidney/metabolism , Male , Mice , Mice, Knockout , Organ Specificity , Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Sympathetic Nervous System/physiology
7.
Osteoarthritis Cartilage ; 21(12): 1904-12, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24455780

ABSTRACT

OBJECTIVE: Marked differences exist between human knee and ankle joints regarding risks and progression of osteoarthritis (OA). Pathomechanisms of degenerative joint disease may therefore differ in these joints, due to differences in tissue structure and function. Focusing on structural issues, which are design goals for tissue engineering, we compared cell and matrix morphologies in different anatomical sites of adult human knee and ankle joints. METHODS: Osteochondral explants were acquired from knee and ankle joints of deceased persons aged 20-40 years and analyzed for cell, matrix and tissue morphology using confocal and electron microscopy (EM) and unbiased stereological methods. Morphological variations disclosing an association between joint type (knee vs ankle) and biomechanical role (convex vs concave articular surfaces) were identified by a 2-way analysis of variance (ANOVA) and a post-hoc analysis. RESULTS: Knee cartilage exhibited higher cell densities in the superficial zone than ankle cartilage. In the transitional zone, higher cell densities were observed in association with convex vs concave articular surfaces, without significant differences between knee and ankle cartilage. Highly uniform cell and matrix morphologies were evident throughout the radial zone in the knee and ankle, regardless of tissue biomechanical role. Throughout the knee and ankle cartilage sampled, chondron density was remarkably constant at approximately 4.2 × 10(6) chondrons/cm(3). CONCLUSION: Variation in cartilage cell and matrix morphologies with changing joint and biomechanical environments suggests that tissue structural adaptations are performed primarily by the superficial and transitional zones. Data may aid the development of site-specific cartilage tissue engineering, and help to identify conditions where OA is likely to occur.


Subject(s)
Ankle Joint/ultrastructure , Cartilage, Articular/diagnostic imaging , Chondrocytes/ultrastructure , Extracellular Matrix/ultrastructure , Knee Joint/ultrastructure , Adaptation, Physiological , Adult , Biomechanical Phenomena , Cartilage, Articular/cytology , Cell Count , Female , Humans , Male , Microscopy, Confocal , Microscopy, Electron , Ultrasonography , Young Adult
8.
Neurotox Res ; 21(1): 41-8, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21717232

ABSTRACT

Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuroprotective peptide exerting protective effects in neuronal injuries. We have provided evidence that PACAP is neuroprotective in several models of retinal degeneration in vivo. Our previous studies showed that PACAP treatment ameliorated the damaging effects of chronic hypoperfusion modeled by permanent bilateral carotid artery occlusion. We have also demonstrated in earlier studies that treatment with PACAP antagonists further aggravates retinal lesions. It has been shown that PACAP deficient mice have larger infarct size in cerebral ischemia. The aim of this study was to compare the degree of retinal damage in wild type and PACAP deficient mice in ischemic retinal insult. Mice underwent 10 min of bilateral carotid artery occlusion followed by 2-week reperfusion period. Retinas were then processed for histological analysis. It was found that PACAP deficient mice had significantly greater retinal damage, as shown by the thickness of the whole retina, the morphometric analysis of the individual retinal layers, and the cell numbers in the inner nuclear and ganglion cell layers. Exogenous PACAP administration could partially protect against retinal degeneration in PACAP deficient mice. These results clearly show that endogenous PACAP reacts as a stress-response peptide that is necessary for endogenous protection against different retinal insults.


Subject(s)
Ischemia/etiology , Neuroprotective Agents , Pituitary Adenylate Cyclase-Activating Polypeptide/deficiency , Retinal Degeneration/etiology , Retinal Vessels , Animals , Disease Models, Animal , Mice , Mice, Knockout , Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Retina/pathology , Retinal Degeneration/pathology
9.
Neurotox Res ; 21(4): 435-44, 2012 May.
Article in English | MEDLINE | ID: mdl-22203609

ABSTRACT

Pituitary adenylate cyclase activating polypeptide (PACAP) is a multifunctional neuropeptide with well-known neuroprotective and neurotrophic effects. The involvement of PACAP in sensory processing has also been documented, but little is known about its effects in the auditory system. PACAP and its specific receptor (PAC1) are present in the cochlea and in brain structures involved in auditory pathways. Recently, we have shown that PACAP protects cochlear cells against oxidative stress-induced apoptosis. The endolymphatic Ca(2+) concentration controlled by Ca(2+) buffers of the hair cells is essential for the normal hearing processes. In this study we examined the localization of PAC1 receptor and Ca(2+) buffering proteins (parvalbumin, calretinin, calbindin) in the inner ear of 5-day-old PACAP-deficient mice compared with wild-type mice in order to get a closer insight into the effect of endogenous PACAP in the cochlear function. We did not find differences in the distribution pattern of PAC1 receptors between the two groups, but wild-type animals showed significantly higher PAC1 receptor expression. In contrast, inner and outer hair cells of PACAP-deficient mice showed more pronounced parvalbumin, calbindin, and calretinin immunopositivity compared with wild-type mice. Elevated endolymphatic Ca(2+) is deleterious for cochlear function, while the high concentration of Ca(2+) buffers in hair cells may offer protection. The increased immunoreactivity of Ca(2+) binding proteins in the absence of PACAP provide further evidence the important role of PACAP in the hearing processes.


Subject(s)
Calcium-Binding Proteins/metabolism , Ear, Inner/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/physiology , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Animals , Calbindin 2 , Calbindins , Cochlea/metabolism , Ear, Inner/cytology , Hair Cells, Auditory/metabolism , Mice , Mice, Inbred ICR , Mice, Knockout , Parvalbumins/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , S100 Calcium Binding Protein G/metabolism
10.
Eur Cell Mater ; 22: 302-19; discussion 319-20, 2011 Nov 24.
Article in English | MEDLINE | ID: mdl-22116649

ABSTRACT

Mesenchymal stromal cells (MSCs), which reside within various tissues, are utilized in the engineering of cartilage tissue. Dexamethasone (DEX)--a synthetic glucocorticoid--is almost invariably applied to potentiate the growth-factor-induced chondrogenesis of MSCs in vitro, albeit that this effect has been experimentally demonstrated only for transforming-growth-factor-beta (TGF-ß)-stimulated bone-marrow-derived MSCs. Clinically, systemic glucocorticoid therapy is associated with untoward side effects (e.g., bone loss and increased susceptibility to infection). Hence, the use of these agents should be avoided or limited. We hypothesize that the influence of DEX on the chondrogenesis of MSCs depends upon their tissue origin and microenvironment [absence or presence of an extracellular matrix (ECM)], as well as upon the nature of the growth factor. We investigated its effects upon the TGF-ß1- and bone-morphogenetic-protein 2 (BMP-2)-induced chondrogenesis of MSCs as a function of tissue source (bone marrow vs. synovium) and microenvironment [cell aggregates (no ECM) vs. explants (presence of a natural ECM)]. In aggregates of bone-marrow-derived MSCs, DEX enhanced TGF-ß1-induced chondrogenesis by an up-regulation of cartilaginous genes, but had little influence on the BMP-2-induced response. In aggregates of synovial MSCs, DEX exerted no remarkable effect on either TGF-ß1- or BMP-2-induced chondrogenesis. In synovial explants, DEX inhibited BMP-2-induced chondrogenesis almost completely, but had little impact on the TGF-ß1-induced response. Our data reveal that steroids are not indispensable for the chondrogenesis of MSCs in vitro. Their influence is context dependent (tissue source of the MSCs, their microenvironment and the nature of the growth-factor). This finding has important implications for MSC based approaches to cartilage repair.


Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Cellular Microenvironment , Chondrogenesis/drug effects , Dexamethasone/pharmacology , Glucocorticoids/pharmacology , Mesenchymal Stem Cells/drug effects , Transforming Growth Factor beta1/pharmacology , Animals , Antigens, Differentiation/genetics , Antigens, Differentiation/metabolism , Bone Marrow Cells/drug effects , Bone Marrow Cells/physiology , Cattle , Cells, Cultured , Collagen/genetics , Collagen/metabolism , Extracellular Matrix/metabolism , Gene Expression/drug effects , Gene Expression Profiling , Glycosaminoglycans/metabolism , Joint Capsule/cytology , Joint Capsule/metabolism , Mesenchymal Stem Cells/metabolism , Mesenchymal Stem Cells/physiology , Organ Specificity , Tissue Culture Techniques
11.
Neuroscience ; 172: 554-61, 2011 Jan 13.
Article in English | MEDLINE | ID: mdl-20974227

ABSTRACT

Hippocampal neurogenesis occurs throughout life in mammals and has pivotal roles in brain functions. An enriched environment stimulates hippocampal neurogenesis, but the exact mechanisms are still unclear. The present study investigated the role of pituitary adenylate cyclase-activating polypeptide (PACAP) in adult hippocampal neurogenesis under standard or enriched rearing conditions. Rearing in the enriched conditions from 4-weeks old for 4-weeks increased the survival of newly divided cells in the subgranular zone and granule cell layer of the dentate gyrus of wild-type and PACAP-knockout (PACAP-/-) mice. The increase in the survival in the granule cell layer was less in PACAP-/- mice than in the wild-type mice. In contrast, the proliferation of newly divided cells in mice reared in the standard and enriched conditions did not differ between the wild-type and PACAP-/- mice. Regarding the differentiation of newborn cells in the dentate gyrus, most of the newly divided cells exhibited the neuronal phenotype in both the wild-type and PACAP-/- mice under standard and enriched conditions. These findings suggest that endogenous PACAP is partly involved in the survival of the enriched environment-induced generation, but not in the basal rate, of newborn cells in the dentate gyrus of the adult hippocampus.


Subject(s)
Hippocampus/metabolism , Neurogenesis , Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Animals , Cell Division/genetics , Cellular Senescence/genetics , Dentate Gyrus/cytology , Dentate Gyrus/metabolism , Environment , Environment, Controlled , Hippocampus/cytology , Male , Mice , Mice, Inbred ICR , Mice, Knockout , Neural Stem Cells/cytology , Neural Stem Cells/metabolism , Neurogenesis/genetics , Phenotype , Physical Stimulation , Pituitary Adenylate Cyclase-Activating Polypeptide/deficiency
12.
Neuropeptides ; 44(5): 363-71, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20621353

ABSTRACT

Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) and its receptors (PAC1 and VPAC) have been shown in the spinal dorsal horn, dorsal root ganglia and sensory nerve terminals. Data concerning the role of PACAP in central pain transmission are controversial and we have recently published its divergent peripheral effects on nociceptive processes. The aim of the present study was to investigate acute somatic and visceral nocifensive behaviours, partial sciatic nerve ligation-evoked chronic neuropathic, as well as resiniferatoxin-induced inflammatory thermal and mechanical hyperalgesia in PACAP deficient (PACAP(-/-)) mice to elucidate its overall function in pain transmission. Neuronal activation was investigated with c-Fos immunohistochemistry. Paw lickings in the early (0-5 min) and late (20-45 min) phases of the formalin test were markedly reduced in PACAP(-/-) mice. Acetic acid-evoked abdominal contractions referring to acute visceral chemonociception was also significantly attenuated in PACAP knockout animals. In both models, the excitatory role of PACAP was supported by markedly greater c-Fos expression in the periaqueductal grey and the somatosensory cortex. In PACAP-deficient animals neuropathic mechanical hyperalgesia was absent, while c-Fos immunopositivity 20 days after the operation was significantly higher. In this chronic model, these neurons are likely to indicate the activation of secondary inhibitory pathways. Intraplantarly injected resiniferatoxin-evoked mechanical hyperalgesia involving both peripheral and central processes was decreased, but thermal allodynia mediated by only peripheral mechanisms was increased in PACAP(-/-) mice. These data clearly demonstrate an overall excitatory role of PACAP in pain transmission originating from both exteroceptive and interoceptive areas, it is also involved in central sensitization. This can be explained by the signal transduction mechanisms of its identified receptors, both PAC1 and VPAC activation leads to neuronal excitation. In contrast, it is an inhibitory mediator at the level of the peripheral sensory nerve endings and decreases their sensitization to heat with presently unknown mechanisms.


Subject(s)
Behavior, Animal/physiology , Hyperalgesia/metabolism , Neurons/metabolism , Nociceptors/physiology , Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Analysis of Variance , Animals , Hot Temperature , Hyperalgesia/genetics , Hyperalgesia/physiopathology , Immunohistochemistry , Mice , Mice, Knockout , Pain Measurement , Periaqueductal Gray/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Proto-Oncogene Proteins c-fos/metabolism , Somatosensory Cortex/metabolism
13.
Osteoarthritis Cartilage ; 15(10): 1178-89, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17502159

ABSTRACT

OBJECTIVE: In a recent study, we demonstrated that mesenchymal stem cells (MSCs) derived from the synovial membranes of bovine shoulder joints could differentiate into chondrocytes when cultured in alginate. The purpose of the present study was to establish the conditions under which synovial MSCs derived from aging human donors can be induced to undergo chondrogenic differentiation using the same alginate system. METHODS: MSCs were obtained by digesting the knee-joint synovial membranes of osteoarthritic human donors (aged 59-76 years), and expanded in monolayer cultures. The cells were then seeded at a numerical density of 4x10(6)/ml within discs of 2% alginate, which were cultured in serum-containing or serum-free medium (the latter being supplemented with 1% insulin, transferrin, selenium (ITS). The chondrogenic differentiation capacity of the cells was tested by exposing them to the morphogens transforming growth factor-beta1 (TGF-beta1), TGF-beta2, TGF-beta3, insulin-like growth factor-1 (IGF-1), bone morphogenetic protein-2 (BMP-2) and BMP-7, as well as to the synthetic glucocorticoid dexamethasone. The relative mRNA levels of collagen types I and II, of aggrecan and of Sox9 were determined quantitatively by the real-time polymerase chain reaction (PCR). The extracellular deposition of proteoglycans was evaluated histologically after staining with Toluidine Blue, and that of type-II collagen by immunohistochemistry. RESULTS: BMP-2 induced the chondrogenic differentiation of human synovial MSCs in a dose-dependent manner. The response elicited by BMP-7 was comparable. Both of these agents were more potent than TGF-beta1. A higher level of BMP-2-induced chondrogenic differentiation was achieved in the absence than in the presence of serum. In the presence of dexamethasone, the BMP-2-induced expression of mRNAs for aggrecan and type-II collagen was suppressed; the weaker TGF-beta1-induced expression of these chondrogenic markers was not obviously affected. CONCLUSIONS: We have demonstrated that synovial MSCs derived from the knee joints of aging human donors possess chondrogenic potential. Under serum-free culturing conditions and in the absence of dexamethasone, BMP-2 and BMP-7 were the most potent inducers of this transformation process.


Subject(s)
Bone Morphogenetic Proteins/metabolism , Chondrocytes/metabolism , Chondrogenesis/physiology , Mesenchymal Stem Cells/cytology , Transforming Growth Factor beta1/physiology , Transforming Growth Factor beta/metabolism , Aged , Bone Morphogenetic Protein 2 , Bone Morphogenetic Protein 7 , Cartilage, Articular/metabolism , Cell Culture Techniques , Humans , Mesenchymal Stem Cells/metabolism , Middle Aged , Polymerase Chain Reaction , Statistics as Topic , Synovial Membrane/physiology
14.
Mol Psychiatry ; 12(11): 1026-32, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17387318

ABSTRACT

Pituitary adenylate cyclase-activating polypeptide (PACAP, ADCYAP1: adenylate cyclase-activating polypeptide 1), a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. Here, we provide evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia. We studied the effects of the associated polymorphism in the PACAP gene on neurobiological traits related to risk for schizophrenia. This allele of the PACAP gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in PACAP knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in PACAP signaling might contribute to the pathogenesis of schizophrenia.


Subject(s)
Genetic Predisposition to Disease , Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Polymorphism, Single Nucleotide/genetics , Schizophrenia/genetics , Adult , Alleles , Animals , Antipsychotic Agents/administration & dosage , Behavior, Animal , Chi-Square Distribution , Disease Models, Animal , Female , Gene Frequency , Humans , Magnetic Resonance Imaging/methods , Male , Mice , Mice, Knockout , Middle Aged , Motor Activity/drug effects , Motor Activity/genetics , Neural Inhibition/drug effects , Neural Inhibition/genetics , Pituitary Adenylate Cyclase-Activating Polypeptide/deficiency , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Risperidone/administration & dosage , Schizophrenia/pathology , Schizophrenia/physiopathology
15.
Mol Psychiatry ; 12(4): 398-407, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17389905

ABSTRACT

Disrupted-in-schizophrenia 1 (DISC1) is a gene disrupted by a (1;11) (q42.1;q14.3) translocation that segregates with major psychiatric disorders in a Scottish family. To investigate how DISC1 confers susceptibility to psychiatric disorders, we previously identified fasciculation and elongation protein zeta-1 and Kendrin as DISC1-interacting molecules in a yeast two-hybrid screen of a human brain complementary DNA library. Here, we have further identified a novel DISC1-interacting protein, termed DISC1-Binding Zinc-finger protein (DBZ), which has a predicted C(2)H(2)-type zinc-finger motif and coiled-coil domains. DBZ was co-immunoprecipitated with DISC1 in lysates of PC12 cells and rat brain tissue. The domain of DISC1 interacting with DBZ was close to the translocation breakpoint in the DISC1 gene. DBZ messenger RNA (mRNA) was expressed in human brains, but not in peripheral tissues. In situ hybridization revealed high expression of DBZ mRNA in the hippocampus, olfactory tubercle, cerebral cortex and striatum in rats. Because this pattern of localization was similar to that of the pituitary adenylate cyclase (PAC(1)) receptor for pituitary adenylate cyclase-activating polypeptide (PACAP), which has recently been implicated in neuropsychological functions, we examined whether DISC1/DBZ interaction was involved in the PACAP signaling pathway. PACAP upregulated DISC1 expression and markedly reduced the association between DISC1 and DBZ in PC12 cells. A DISC1-binding domain of DBZ reduced the neurite length in PC12 cells after PACAP stimulation and in primary cultured hippocampal neurons. The present results provide some new molecular insights into the mechanisms of neuronal development and neuropsychiatric disorders.


Subject(s)
Nerve Tissue Proteins/metabolism , Neurites/physiology , Zinc Fingers/physiology , Animals , Brain/cytology , Cells, Cultured , Green Fluorescent Proteins/metabolism , Humans , Immunohistochemistry , In Situ Hybridization , Nerve Tissue Proteins/genetics , Neurons/cytology , Protein Binding , Rats , Transfection , Two-Hybrid System Techniques
16.
Gut ; 50(3): 413-9, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11839724

ABSTRACT

BACKGROUND AND AIMS: Iron is stored in hepatocytes in the form of ferritin and haemosiderin. There is a marked increase in iron rich haemosiderin in iron overloaded livers, and ferric iron in amounts exceeding the ferritin and haemosiderin binding capacity may promote free radical generation, causing cellular damage. The aim of this study was to characterise hepatic haemosiderin using four antibodies specific for either native or denatured H/L-ferritin subunits. METHODS: Ferritin and haemosiderin were prepared from the livers of three patients with post-transfusional iron overload. The assembled ferritin molecules were analysed by non-denaturing polyacrylamide gel electrophoresis (PAGE)-immunoblotting. Ferritin subunits in the haemosiderin fraction were assessed by denaturing sodium dodecyl sulphate (SDS)-PAGE-immunoblotting. Distribution of native and denatured ferritin subunits in hepatocytes was examined by immunogold electron microscopy. RESULTS: Non-denaturing PAGE-immunoblot analyses showed that the assembled liver ferritins were recognised by the antibodies for native ferritins and not by those for the denatured subunits. Both SDS-PAGE-immunoblot and immunogold electron microscopic analyses disclosed that haemosiderin of iron overloaded liver reacted predominantly to the monoclonal antibody for the denatured H-ferritin subunit, to a lesser degree to that for denatured L-ferritin, and very weakly, if any, with antibodies for native H-ferritin or L-ferritin. CONCLUSIONS: These results suggest that in iron overloaded liver, haemosiderin consists predominantly of denatured H-ferritin subunits.


Subject(s)
Ferritins/analysis , Hemosiderin/analysis , Iron Overload/metabolism , Liver/chemistry , Adult , Antibodies, Monoclonal/immunology , Antibody Specificity , Apoferritins , Ferritins/immunology , Hepatocytes/chemistry , Hepatocytes/ultrastructure , Humans , Iron Overload/pathology , Male , Middle Aged , Protein Denaturation
17.
Proc Natl Acad Sci U S A ; 98(23): 13355-60, 2001 Nov 06.
Article in English | MEDLINE | ID: mdl-11687615

ABSTRACT

Pituitary adenylate cyclase-activating polypeptide (PACAP) has been conserved remarkably during evolution and is widely expressed in the mammalian brain. In Drosophila, mutation of the PACAP homologue results in behavioral defects, including impaired olfaction-associated learning and changes in ethanol sensitivity. Here, we report the generation of mice lacking the PACAP gene (PACAP(-/-)). PACAP(-/-) mice were born in the expected Mendelian ratios but had a high early-mortality rate. The surviving adult PACAP(-/-) mice displayed remarkable behavioral changes; they exhibited hyperactive and explosive jumping behaviors in an open field, increased exploratory behavior, and less anxiety in the elevated plus maze, emergence, and novel-object tests. Analysis of PACAP(-/-) mice brains revealed that the serotonin metabolite 5-hydroxyindoleacetic acid was slightly decreased in the cortex and striatum compared with wild-type mice. The present study provides evidence that PACAP plays a previously uncharacterized role in the regulation of psychomotor behaviors.


Subject(s)
Neuropeptides/physiology , Psychomotor Performance , Animals , Base Sequence , Brain/metabolism , Catalepsy/chemically induced , DNA Primers , Haloperidol/pharmacology , Hydroxyindoleacetic Acid/metabolism , Mice , Mice, Knockout , Neuropeptides/genetics , Pituitary Adenylate Cyclase-Activating Polypeptide , Psychomotor Performance/drug effects , Serotonin/metabolism
18.
Biochem Biophys Res Commun ; 285(3): 656-61, 2001 Jul 20.
Article in English | MEDLINE | ID: mdl-11453643

ABSTRACT

We have recently shown that in PC12 cells, PACAP and NGF synergistically increase PACAP gene transcription and mRNA level, and that the MAPK/ERK kinase inhibitor PD98059 blocks the PACAP mRNA expression induced by either PACAP or NGF, but not that induced by the combination, suggesting involvement of multiple signaling pathways. Here we show that the p38 MAPK inhibitor SB203580 almost completely inhibits the PACAP mRNA expression induced by PACAP alone or in combination with NGF. PACAP induces neurite outgrowth and potentiates NGF-induced neurite outgrowth in PC12h cells. Unlike the case for the PACAP mRNA expression, SB203580 did not affect, but PD98059 reduced, PACAP and NGF-induced neurite outgrowth. These results indicate that PACAP receptors are coupled to the p38 signaling pathway, and that p38 plays a key role in the regulation of PACAP gene expression, while ERK, but not p38, MAPK is involved in PACAP and NGF-induced neurite outgrowth.


Subject(s)
Mitogen-Activated Protein Kinases/metabolism , Nerve Growth Factor/pharmacology , Neuropeptides/metabolism , Neuropeptides/pharmacology , RNA, Messenger/biosynthesis , Animals , Dose-Response Relationship, Drug , Drug Synergism , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Gene Expression/drug effects , Imidazoles/pharmacology , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Neurites/drug effects , Neuropeptides/genetics , PC12 Cells , Pituitary Adenylate Cyclase-Activating Polypeptide , Pyridines/pharmacology , Rats , Signal Transduction/drug effects , Signal Transduction/physiology , p38 Mitogen-Activated Protein Kinases
19.
Clin Exp Immunol ; 124(2): 282-9, 2001 May.
Article in English | MEDLINE | ID: mdl-11422206

ABSTRACT

High-dose intravenous immunoglobulin (IVIG) therapy has been effective in many autoimmune and systemic inflammatory diseases including polymyositis (PM) and dermatomyositis (DM). In the present study we evaluated the efficacy of IVIG using experimental models of PM and DM. An experimental autoimmune myositis (EAM) model was produced in SJL/J mice by an immunization with rabbit myosin B (MB) fraction. In this model, the plasma level of anti-MB antibody was elevated, and mouse IgG and complement C3 were deposited in the muscle fibres. Administration of IVIG dose-dependently reduced the incidences of necrotic and inflammatory changes in the skeletal muscle. IVIG treatment also decreased the elevation of anti-MB antibody level, as well as the deposition of IgG and C3. We next evaluated the effect of IVIG in adoptive EAM mice made by an intravenous injection of lymph node cells previously stimulated with MB. Adoptive EAM mice showed similar lesions in skeletal muscle as EAM mice and IVIG inhibited the lesion development. In vitro experiments demonstrated that IVIG inhibited complement-mediated lysis of human erythrocytes sensitized with anti-human erythrocyte antibodies. The binding of C1q, C4 and C3 to the same cells was also inhibited by IVIG. Taken together these findings suggest that IVIG prevents the development of myositis in EAM and adoptive EAM models by several mechanisms, such as reducing anti-myosin antibody and by blocking complement activation. Our present findings might account for the clinical efficacy of IVIG in PM and DM patients.


Subject(s)
Complement C3/metabolism , Immunoglobulin G/metabolism , Immunoglobulins, Intravenous/therapeutic use , Myosins/immunology , Myositis/therapy , Nervous System Autoimmune Disease, Experimental/therapy , Adoptive Transfer , Animals , Autoantibodies/blood , Complement Activation , Male , Mice , Muscle, Skeletal/pathology , T-Lymphocytes/transplantation
20.
Biochim Biophys Acta ; 1509(1-2): 195-202, 2000 Dec 20.
Article in English | MEDLINE | ID: mdl-11118531

ABSTRACT

To study desensitization and glycosylation of the type I pituitary adenylate cyclase-activating polypeptide (PACAP) receptor (PAC(1)R), a hemagglutinin (HA) epitope was inserted within the N-terminal extracellular domain, allowing immunological detection of PAC(1)R both in intact and permeabilized cells. PAC(1)R was tagged without loss of functions in ligand binding and ligand-stimulated cAMP production. In transiently transfected COS-7 cells, PAC(1)R was localized both in the plasma membrane and the cytoplasm around the nucleus. By immunoblot analysis, the immunoreactive bands with relative molecular masses ranging from 45 to 70 kDa were detected in the membrane fractions of PAC(1)R-expressing COS-7 cells. Digestion of the membranes with endoglycosidase F or treatment of the cells with tunicamycin decreased the size of the receptor to major bands of smaller size (approximately 45 and 48 kDa), suggesting that these two forms of PAC(1)R represent core proteins. Flow cytometric analysis indicated that the agonist promoted a disappearance of cell surface receptor. In accordance with this observation, preexposure of cells to PACAP38 induced a desensitization of PAC(1)R to the agonist response, although it did not cause a reduction in PAC(1)R mRNA or protein level and even slightly elevated them. These results suggest that agonist-induced desensitization of PAC(1)R involves the receptor sequestration.


Subject(s)
Receptors, Pituitary Hormone/metabolism , Amino Acid Sequence , Animals , Base Sequence , CHO Cells , COS Cells , Cell Membrane/metabolism , Cricetinae , Cytoplasm/metabolism , Desensitization, Immunologic , Flow Cytometry , Glycosylation , Hemagglutinins/immunology , Immunoblotting , Mice , Molecular Sequence Data , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Pituitary Hormone/biosynthesis , Receptors, Pituitary Hormone/immunology , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...